

# Hepatitis G virus infection in India: prevalence and phylogenetic analysis based on 5' non-coding region

VIDYA A ARANKALLE, TEJASWINI M DESHMUKH, LEENATA P CHOBE,  
MANDEEP S CHADHA, ATUL M WALIMBE

Hepatitis Division, National Institute of Virology, 20-A Dr Ambedkar Road, Pune 411 001

**Objectives:** To determine the prevalence of hepatitis G virus (HGV) infection in western India and to carry out phylogenetic analysis of HGV isolates. **Methods:** Reverse transcription-polymerase chain reaction (RT-PCR) assay was used to detect HGV RNA in serum samples obtained from paid plasma donors, patients with hemophilia and voluntary blood donors. Nine Indian and one Kenyan HGV RNA-positive samples were sequenced in the 5' non-coding region (5'-NCR). Phylogenetic analysis based on the comparison of a 101 nucleotide fragment from a large number of HGV isolates from 22 countries (including Indian and Kenyan sequences obtained during the present study) was carried out.

**Results:** HGV RNA positivity rates among paid plasma donors from a commercial plasmapheresis unit (7/43, 16.3%) and patients with hemophilia (5/44, 11.4%) were significantly higher than that in voluntary blood donors (0/51;  $p=0.003$  and 0.019, respectively). Among patients with acute non-A to E hepatitis and fulminant hepatic failure, 1 of 50 and 1 of 28 were HGV RNA-positive, whereas 6 of 49 (12%) patients with chronic liver disease had circulating HGV RNA. All Indian isolates belonged to genotype 2, whereas the Kenyan isolate formed a distinct branch within genotype 1 consisting of African isolates. **Conclusion:** Our results suggest existence of parenteral transmission of HGV in the Indian population. HGV was not an important cause of acute non-A to E hepatitis or fulminant hepatic failure among the patients investigated. Genotype 2 seems to be the most prevalent genotype in western India. [Indian J Gastroenterol 2001;20:13-17]

**Key words:** GBV-C/HGV, genotypes, viral hepatitis

Although the clinical significance of infection with the hepatitis G virus (HGV) is not yet clearly understood, the virus appears to be associated with both acute and chronic hepatitis. Association of HGV with fulminant hepatic failure (FHF) remains controversial.<sup>1</sup> There is evidence for the parenteral transmission of HGV.<sup>2</sup>

HGV has a positive-sense RNA genome, approximately 9.4 kilobases in length, that contains a 458-nucleotide long 5' non-coding region (NCR), a single open reading frame (ORF) encoding a polyprotein of about

2900 amino acids, and a 3'-NCR of 315 nucleotides. Genotypic classification of HGV isolates identified worldwide is being attempted, mostly using the 5'-NCR region.<sup>3-8</sup>

We have attempted to determine the prevalence of HGV RNA among patients with hepatitis, certain high-risk individuals and voluntary blood donors from western India. We sequenced 9 Indian HGV isolates and one isolate from a Kenyan patient touring India (Kenyan isolate) in the 5' NCR and determined the phylogenetic status of these isolates in comparison with those sequenced earlier from different geographic areas.

## Methods

Serum samples stored at -20°C were tested for HGV RNA. These were obtained from voluntary blood donors (n=51), hemophiliacs (44) and patients suffering from chronic liver diseases (49); these had been collected in Pune in 1997. Stored sera from paid plasma donors (43) with evidence of exposure to parenterally transmitted human immunodeficiency (HIV)<sup>9</sup> and hepatitis C viruses (HCV)<sup>10</sup> from a commercial plasmapheresis unit in 1989 were also tested. In addition, patients with non-A to E acute viral hepatitis (50) and fulminant hepatic failure (FHF; 28) from Pune, who constituted a subset of acute viral hepatitis cases investigated by us during the period 1994-97, were also investigated. In addition, serum from a Kenyan tourist visiting India for the first time, obtained 9 days after arrival for a liver illness (?subacute hepatic failure, ?reactivation of chronic liver disease), was also tested.

## Polymerase chain reaction

All serum samples were tested for the presence of HGV RNA employing nested reverse transcription-polymerase chain reaction (RT-PCR). RNA was isolated using Trizol reagent (GIBCO BRL, Life Technologies, Rockville, MD, USA) according to the manufacturer's instructions. cDNA synthesis was carried out at 42°C for one hour using the external antisense primer. This was followed by 35 cycles at 94°C for 1 minute, 55°C for 2 min and 72°C for 3 min, for first-round PCR and 30 cycles for the second-round PCR. The PCR products were analyzed by 2% agarose gel electrophoresis and visualized using ethidium bromide. The primers used were: External sense primer (89-106): 5' AGG TGG TGG ATG

**Table 1: HGV isolates compared in this study**

Country	No. of isolates	Accession Numbers
Australia	1	AF006975
China	1	U86154
Egypt	2	AB004505, AB004507
France	1	AF104403
Germany	1	AF006967
Greece	3	AF006966, AF006984, AF006985
Ghana	4	AB004508, AB004509, AB004511, AB004514
India	9	Present study*
Japan	5	AB012005, AB012010, AB012013, AB012022, AB004521
Kenya	1	Present study**
Korea	2	AB004522, AB004523
Myanmar	4	AB018651, AB018652, AB018655, AB018665
Nepal	2	AB004527, AB004528
Pakistan	2	AF003154, AF003162
Peru	2	AF006977, AF006978
Sweden	4	AF063855, AF063860, AF063861, AF063862
Spain	7	AF038789, AF038796, AF038800, AB004529, AF038782-84
Thailand	3	U91713, U91714, U917122
UK	5	AF003168, AF003171, AF003175- AF003177
USA	2	AB004530, AB004532
Vietnam	4	AB013189, AB013193, AB013203, AB013233
Zaire	2	AF003184, AF003186
Total	67	

\*Accession Numbers: AF148543-AF148551

\*\*Accession Number: AF148552

**GGT GAT 3'**

External antisense primer (512-492): 5' TGC CAC CCG CCC TCA CCC GAA 3'

Internal sense primer (114-135) 5' TGG TAG GTC GTA AAT CCC GGT 3'

Internal antisense primer (457-436): 5' GGA GCT GGG TGG CCT CAT GCTT 3'

**Sequencing:** Amplified PCR products (343 bases) were purified using mini column (*Wizard*; Promega, Madison, WI, USA) and sequenced in both directions using Taq dye terminator cycle sequencing kit (Perkin Elmer, NJ, USA) and an automatic sequencer (301 ABI; Perkin Elmer, NJ, USA).

**Phylogenetic analysis**

Phylogenetic analysis of HGV isolates from this study and previously described HGV DNA sequences obtained from the Genbank database was done using programs available in the software MEGA<sup>11</sup> and PHYLIP version 3.5c.<sup>12</sup> In MEGA, Jukes-Cantor (JC) algorithm was utilized employing the neighbor joining (NJ) method, and the reliability of different phylogenetic groupings was evaluated using the bootstrap test (1000 bootstrap replications). In PHYLIP, JC algorithm employing the NJ

method with or without mid-point rooted was used; the results obtained were evaluated using bootstrap analysis (SEQBOOT, 1000 bootstrap replications).

The phylogenetic analysis was carried out on the basis of comparisons of 340-nucleotide and 101-nucleotide fragments of the 5'-NCR of HGV<sup>4</sup> representing all the available HGV sequences.

**Statistical analysis**

Fisher's exact test (one-tailed) was used to compare proportions.

**Results****Prevalence of HGV RNA**

Sera from none of the 51 voluntary blood donors tested positive for HGV RNA (Table 2); 7/43 (16.3%) paid plasma donors ( $p=0.0031$  as compared to voluntary donors) and 5/44 (11.4%) hemophiliacs ( $p=0.0187$ ) tested positive.

HGV RNA positivity rate in patients with non-A to E acute viral hepatitis (1/50) and FHF (1/28) were no different from that in voluntary blood donors, whereas that in patients with chronic liver disease (6/49; 12.2%) was higher ( $p=0.05$ ). Serum sample from the Kenyan tourist tested positive.

**Phylogenetic analysis**

Ten of the 21 HGV RNA-positive samples (chronic liver disease 4, hemophiliacs 2, paid plasma donor 1, hemodialysis patient 1, non-A to E acute viral hepatitis 1, and the Kenyan tourist) were sequenced.


Analysis of a 101-nucleotide (-366 to -266) region, but not that of a 340-nucleotide 5'-NCR region revealed distinct efficient groups of various isolates (data not shown). Initial analysis was performed with 174 available sequences; for subsequent analysis, only representative sequences from various countries and groups (except those from the present study) were retained.

The 67 isolates analyzed fell into four major groups (genotypes) (Fig). A majority (43/64, 67.2%) belonged to group I (genotype 2); these included all the isolates from Australia (1), Egypt (2) France (1), Germany (1), Greece (3), India (9), Pakistan (2), Peru (2), Spain (7), Sweden (4) and USA (2), and 3 of 5 isolates from the UK, 1 of 2 isolates from Nepal, 1 of 2 isolates from Korea, 2 of 4 isolates from Vietnam and 2 of 4 isolates from Myanmar.

**Table 2: Frequency of HGV RNA positivity**

Category	No. positive / Tested (%; 95% CI)
Voluntary blood donors	0/51
Non-A-E acute viral hepatitis	1/50 (2%, 0% - 5.9%)
Chronic liver disease(s)	6/49 (12.24%, 3% - 21.4%)
FHF	1/28 (3.6%, 0% - 10.4%)
Hemophiliacs	5/44 (11.36%, 1.99% - 20.7%)
Paid plasma donors	7/43 (16.28%, 5.2% - 27.3%)

Figure 1



**Fig: Phylogenetic analysis of the 5'-NCR of 93 HGV isolates employing MEGA software utilizing Jukes-Cantor distance and 1000 bootstrap analysis**

Group II (genotype 4) consisted of 5 isolates (7.8%), including two from Thailand, one from Japan and one each from Myanmar and Vietnam.

Group III (genotype 3; 9 isolates, 14%) included one isolate each from China, Nepal, Thailand, Vietnam, the UK, Korea and Myanmar, and two isolates from Japan.

Group IV (genotype 1; 10 isolates, 15.6%) included mainly African isolates (Zaire, Ghana and Kenya), 1 of 5 isolates from the UK and 2 isolates from Japan.

Of the HGV isolates compared, the UK and Myanmar isolates segregated into three genotypes, i.e., 1, 3, 2 and 2, 4, 3, respectively, whereas the Nepalese, Korean and Thai isolates grouped into two genotypes. Though isolates from Zaire, Ghana and Kenya were of genotype 1, isolates from another African country, Egypt, clustered in genotype 2.

## Discussion

A substantial proportion of patients with acute viral hepatitis and FHF from India test negative for known hepatitis viruses, i.e., A to E.<sup>13,14</sup> HGV RNA testing of 50 patients with non-A to E acute viral hepatitis showed that HGV was not responsible for hepatitis in most of them, only one being HGV RNA positive. This is in contrast to reports from Argentina (30.6%)<sup>15</sup> and Italy (39%)<sup>16</sup> showing noticeably higher positivity rates. However, studies from the US,<sup>17</sup> Japan<sup>18,19</sup> and Brazil<sup>20</sup> did not show HGV as an important cause of acute viral hepatitis. HGV does not appear to be an important etiologic agent for FHF in the Indian patients investigated (1/28). A preliminary report from Delhi showed HGV RNA in 2 of 16 patients with non-A to E FHF.<sup>21</sup>

We found higher HGV RNA positivity rate (12.2%) among patients with chronic liver disease. A study from northern India<sup>22</sup> also found 12% HGV RNA positivity among patients with cirrhosis; however, 24% of healthy blood donors in that study were HGV RNA-positive.

Significantly higher HGV RNA positivity among hemophiliacs and paid plasma donors with a high prevalence of antibodies to HIV<sup>9</sup> and HCV<sup>10</sup> confirms the importance of parenteral routes in the transmission of HGV. Absence of HGV RNA in 51 voluntary blood donors indicated that, as in Italy,<sup>23</sup> Germany<sup>24</sup> and the US,<sup>25</sup> HGV infection is infrequent in our population. South Africa (11.1%),<sup>26</sup> Vietnam (7.4%)<sup>27</sup> and Brazil (5.8%)<sup>28</sup> reported higher exposure of voluntary blood do-

nors to HGV. In China, a distinct difference between voluntary blood donors (0.8%) and paid donors (7.9%) was noted.<sup>29</sup>

Phylogenetic analysis assesses evolutionary relationship between different viral isolates. Recent studies have shown that, unlike HCV, subgenomic analyses of different regions of the HGV genome do not lead to distinct differentiation of the various isolates.<sup>6,30</sup> Based on the available 5' NCR sequences, Muerhoff *et al*<sup>3</sup> proposed classification of the HGV isolates into three genotypes. In 1997, Smith *et al*<sup>4</sup> and Linnen *et al*<sup>5</sup> compared HGV 5' NCR sequences from a few additional countries, with comparable results. Based on restriction fragment length polymorphism analysis of the 5'-NCR too,<sup>7</sup> HGV isolates were classified into 3 major groups.

The segment of HGV 5'-NCR used for phylogenetic analysis appears crucial for better segregation of HGV isolates into distinct genotypes/groups representing different geographic regions.<sup>4</sup> Our data confirm this finding.

Use of a 148-nucleotide 5'-NCR segment led to the identification of a novel genotype of HGV isolates from Myanmar and Vietnam, the genotype 4; in our 101-nucleotide fragment analysis too, isolates formed a separate group, along with most Thai isolates and a Japanese isolate.

Overall, genotype 2 seems to be highly prevalent and is distributed worldwide. All our Indian isolates belonged to this genotype.

In conclusion, our study suggests that HGV infection has a low prevalence in western India. It confirms the usefulness of an 101-nucleotide fragment of the 5'-NCR in genotyping HGV, and places all Indian isolates in genotype 2. The Kenyan isolate emerged to be a distinct branch of genotype 1 represented mainly by African isolates.

## References

- Hadziyannis SJ. Fulminant hepatitis and the new G/GBV-C flavivirus. *J Viral Hepat* 1998;5:15-9.
- Linnen J, Wages J Jr, Zhang-keck ZY, Fry KE, Krawczynski KZ, Alter H, *et al*. Molecular cloning and disease association of hepatitis G virus: a transfusion transmissible agent. *Science* 1996;271:505-8.
- Muerhoff AS, Simons JN, Leary TP, Erker JC, Chalmers ML, Pilot-Matias TJ, *et al*. Sequence heterogeneity within the 5'-terminal region of the hepatitis GB virus C genome and evidence for genotypes. *J Hepatol* 1996;25:379-84.
- Smith DB, Cuceanus N, Davidson F, Jarvis LM, Mokili JLK, Hamid S, *et al*. Discrimination of hepatitis G virus/GBV-C geographical variants by analysis of the 5' non-coding region. *J Gen Virol* 1997;78:1533-42.
- Linnen JM, Fung K, Fry KE, Mizokami M, Ohba K, Wages JM, *et al*. Sequence variation and phylogenetic analysis of the 5' terminus of hepatitis G virus. *J Viral Hepat* 1997;4:293-302.
- Cong MC, Fried MW, Lambert S, Lopareva EN, Zhan M, Pujol FH, *et al*. Sequence heterogeneity within three different regions of the hepatitis G virus genome. *Virology* 1999;255:250-9.
- Quarleri JF, Mathet VL, Feld M, Ferrario D, Della Latta MP, Verdun R, *et al*. GB virus C/hepatitis G virus groups and subgroups: classification by a restriction fragment length polymorphism method based on phylogenetic analysis of the 5' untranslated region. *J Clin Microbiol* 1999;37:1340-7.
- Naito H, Win KM, Abe K. Identification of a novel genotype of hepatitis G virus in Southeast Asia. *J Clin Microbiol* 1999;37:1217-20.
- Banerjee K, Rodrigues JJ, Israel ZR. Outbreak of HIV seropositivity among commercial plasma donors in Pune, India. *Lancet* 1989;ii:166.
- Jha J, Banerjee K, Arankalle VA. A high prevalence of antibodies to hepatitis C virus among commercial plasma donors from Western India. *J Viral Hepat* 1995;2:257-60.
- Kumar S, Tamura K, Nei M. MEGA (Molecular Evolutionary Genetics Analysis), version 1.02. Pennsylvania: Pennsylvania State University, 1993.
- Felsenstein J. PHYLIP (Phylogeny Inference Package). Manual version 3.5c. Seattle, USA: University of Washington, 1993.
- Arankalle VA, Chobe LP, Jha J, Chadha MS, Banerjee K, Favorov MO, *et al*. Aetiology of acute sporadic non-A, non-B hepatitis in Western India. *J Med Virol* 1993;40:121-5.
- Arankalle VA, Jha J, Favorov MO, Chaudhari A, Fields HA, Banerjee K. Contribution of HEV and HCV in causing fulminant non-A, non-B hepatitis in Western India. *J Viral Hepat* 1995;2:189-92.
- Frider B, Sookoian S, Castano G, Gonzalez J, Flichman D, Viudez P, *et al*. Detection of hepatitis G virus RNA in patients with acute non-A-E hepatitis. *J Viral Hepat* 1998;5:161-4.
- Fiordalisi G, Zanella I, Mantero G. High prevalence of GB virus C infection in a group of Italian patients with hepatitis of unknown etiology. *J Infect Dis* 1996;174:181-3.
- Dawson GJ, Schlauder GG, Pilot-Matias TJ, Thiele D, Leary TP, Murphy P, *et al*. Prevalence studies of GB virus C infection using reverse transcriptase polymerase chain reaction. *J Med Virol* 1996;50:97-103.
- Tanaka M, Nishiguchi S, Tanaka T, Enomoto M, Fukuda K, Takeda T, *et al*. Prevalence of GBV-C and hepatitis G virus variants in patients with fulminant hepatic failure in Japan. *J Hepatol* 1997;27:966-72.
- Tanaka H, Miyano M, Ueda H, Doi R, Mimura K, Nishide I, *et al*. Comparative study of 5' UTR and NS3R primers for the detection of GB virus C/hepatitis G virus RNA in Japanese. *Liver* 1998;18:378-82.
- Pinho JRR, Zanotto PMD, Ferreira JLP, Sumita LM, Carrilho FJ, Da Silva LC, *et al*. High prevalence of GB virus C in Brazil and molecular evidence for intrafamilial transmission. *J Clin Microbiol* 1999;37:1634-7.
- Panda SK, Panigrahi AK, Dasarathy S, Acharya SK. Hepatitis G virus in India. *Lancet* 1996;348:1319.
- Jain A, Kar P, Gopalkrishna V, Gangwal P, Katiyar S, Das BC. Hepatitis G virus (HGV) infection and its pathogenic significance in patients of cirrhosis. *Indian J Med Res* 1999;110:37-42.

23. Prati D, Capelli C, Zanella A, Bosoni P, De Mattei C, Mozz F, et al. Asymptomatic hepatitis G virus infection in blood donors. *Transfusion* 1997;37:1200-4.
24. Seifried E, Bialleck H, Weber H, Kirchmaier CM, Waschke E, Marx S, et al. Prevalence of hepatitis G virus genome in blood donors. *Beitr Infusionsther Transfusionsmed* 1997;34:11-5.
25. Simons JN, Leary TP, Dawson GJ, Pilot-Matias TJ, Muerhoff AS, Schlauder GG, et al. Isolation of novel virus-like sequences associated with human hepatitis. *Nature Med* 1995;1:564-9.
26. Casteling A, Song E, Sim J, Blaauw D, Heyns A, Schweizer R, et al. GB virus C prevalence in blood donors and high risk groups for parenterally transmitted agents from Gauteng, South Africa. *J Med Virol* 1998;55:103-8.
27. Brown KE, Wong S, Buu M, Binh TV, Be TV, Young NS. High prevalence of GB virus C/hepatitis G virus in healthy persons in Ho Chi Minh city, Vietnam. *J Infect Dis* 1997;171:450-3.
28. Bassit L, Kleter B, Ribeiro-dos-Santos G, Maertens G, Sabino E, Chamone D, et al. Hepatitis G virus: prevalence and sequence analysis in blood donors of Sao Paulo, Brazil. *Vox Sang* 1998;74:83-7.
29. Wang HL, Lin DY. Prevalence and genotype of hepatitis G virus in Chinese professional blood donors and hepatitis patients. *J Infect Dis* 1997;175:1229-33.
30. Pickering JM, Thomas HC, Karayannidis P. Genetic diversity between hepatitis G virus isolates: analysis of nucleotide variation in the NS-3 and putative 'core' peptide genes. *J Gen Virol* 1997;78:53-60.

Corresponding author: Dr Arankalle, Assistant Director and Head. Fax: (20) 62 2669. E-mail: aarankalle@hotmail.com

Acknowledgements: The authors thank Dr D A Gadkari, Director, National Institute of Virology, for critical evaluation of the manuscript, and Dr A Kolaskar and Mr P Naik, Bioinformatics Center, Department of Biotechnology, University of Pune for assistance with computer programs and access to Genbank database

Received January 18, 2000. Received in final revised form May 31, 2000. Accepted June 5, 2000

## NEWS AND NOTICES

**The 2nd National Update CME will be held in Chandigarh February 17 and 18, 2001.**

For details contact: Prof Kartar Singh, Chairman, Organizing Committee, Department of Superspeciality of Gastroenterology, Postgraduate Institute of Medical Education and Research, Chandigarh 160 012

Tel: (O) (172) 74 7585 Ext 416  
(R) (172) 54 9744, 78 4545

Fax: (172) 74 4401

**The 20th Conference of the Nepal Medical Association will be held in Kathmandu February 28 - March 3, 2001.**

For details contact: Dr Bimal Kumar Sinha, Organizing Secretary, ANEMECON-20, Post Box No. 189, Exhibition Road, Kathmandu, Nepal

Tel: 977 (1) 22 5860. Fax: 977 (1) 22 5300

E-mail: nma@healthnet.org.np  
<http://www.healthnet.org.np/conferences/ANEMECON-20.html>